Scott Cherry
Payments from drug & device makers
Across 619 payments — averaging $13.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Novartis$1K
- Biogen$735
- Bristol Myers Squibb$585
- Pfizer$437
- Amneal Pharmaceuticals LLC$343
- plus $4K from 37 others
What the payments were for
- Speaking & faculty fees$1242%
- Food & beverage$7,88797%
- Education$1262%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$8,137 in reported general payments places this provider in the 70th percentile of 941 neurology providers in Pennsylvania.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ZeposiaOzanimod Hydrochloride | 18 | $163,212 |
| Avonex (4 Pack)Interferon Beta-1a | 13 | $104,447 |
| GlatopaGlatiramer Acetate | 24 | $67,045 |
| Nurtec OdtRimegepant Sulfate | 17 | $34,434 |
| UbrelvyUbrogepant | 18 | $32,631 |
| Glatiramer Acetate | 13 | $21,184 |
| Emgality PenGalcanezumab-Gnlm | 18 | $12,217 |
| NeuproRotigotine | 11 | $10,286 |
| Clobazam | 13 | $5,775 |
| Pregabalin | 18 | $4,665 |
| Fentanyl | 12 | $4,532 |
| Sumatriptan Succinate | 75 | $4,345 |
| DilantinPhenytoin Sodium Extended | 14 | $4,250 |
| Eletriptan HbrEletriptan Hydrobromide | 12 | $2,925 |
| Butalb-Acetaminoph-Caff-CodeinButalbit/Acetamin/Caff/Codeine | 15 | $2,886 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| E.r. Squibb & Sons, L.L.C.Zeposia | $48 | $163,21218 claims |
| BiogenAvonex (4 Pack) | $735 | $104,44713 claims |
| PfizerNurtec Odt, Dilantin | $437 | $38,68431 claims |
| AbbVieUbrelvy | $1,125 | $32,63118 claims |
| UCB, Inc.Neupro | $234 | $10,28611 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 941 neurology providers in Pennsylvania.
Other neurology in York
- Ravi DukkipatiYork$936K
- David WeismanAbington$9.3M
- Amit Bar-OrPhiladelphia$7.7M
- Thomas LeistPhiladelphia$5.8M
- Jan DrappatzPittsburgh$4M
- Lauren ElmanPhiladelphia$3.3M
- David IrwinPhiladelphia$2.5M
- Paula ClemensPittsburgh$2.1M
- Anoopum GuptaPittsburgh$2M
- Daniel KremensPhiladelphia$1.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.